Skip to main content

Advertisement

SpringerLink
Log in

Development of a Cell Transducible RhoA Inhibitor TAT-C3 Transferase and its Encapsulation in Biocompatible Microspheres to Promote Survival and Enhance Regeneration of Severed Neurons

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

Neurons in post-traumatized mammalian central nervous system show only limited degree of regeneration, which can be attributed to the presence of neurite outgrowth inhibitors in damaged myelin and glial scar, and to the apoptosis of severed central neurons and glial cells during secondary Wallerian degeneration. RhoA GTPase has been implicated as the common denominator in these counter-regeneration events, which shows significant and persistent up-regulation for weeks in injured spinal cord and cerebral infarct after stroke. While the exoenzyme C3 transferase is a potent RhoA inhibitor, its extremely low efficiency of cell entry and degradation in vivo has restricted the therapeutic value. This study aims to circumvent these problems by developing a membrane-permeating form of C3 transferase and a biopolymer-based microsphere depot system for sustainable controlled release of the protein.

Materials and Methods

A membrane-permeating form of C3 transferase was developed by fusing a Tat (trans-activating transcription factor) transduction domain of human immunodeficiency virus to its amino terminal using standard molecular cloning techniques. After confirming efficient cell entry into epithelial and neuroblastoma cells, the resulting recombinant protein TAT-C3 was encapsulated in biocompatible polymer poly(d,l-lactide-co-glycolide) in the form of microspheres by a water-in-oil-in-water (W/O/W) emulsion method. By blending capped and uncapped form of the polymer at different ratios, TAT-C3 protein release profile was modified to suit the expression pattern of endogenous RhoA during CNS injuries. Bioactivity of TAT-C3 released from microspheres was assessed by RhoA ribosylation assay.

Results

In contrast to wild-type C3 transferase, the modified TAT-C3 protein was found to efficiently enter NIH3T3 and N1E-115 neuroblastoma cells as early as 6 hours of incubation. The fusion of TAT sequence to C3 transferase imposed no appreciable effects on its biological activity in promoting neurite outgrowth through RhoA inhibition. Characterization of TAT-C3 encapsulation in various blends of capped/uncapped PLGA polymer revealed the 30:70 formulation to be optimal in attaining a mild initial burst release of 25%, followed by a subsequent average daily release of 2.3% of encapsulated protein over one month, matching the change in RhoA level in severed brain and spinal cord. Importantly, TAT-C3 released from the microspheres remained active up to the first three weeks of incubation.

Conclusion

Enhanced cell entry of TAT-C3 circumvents the need to administer high dose of the protein to site of injury. The encapsulation of TAT-C3 in different blends of capped/uncapped PLGA microspheres allows adjustment of protein release profile to suit the pattern of RhoA expression in injured CNS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. E. Emery, P. Aldana, M. B. Bunge, W. Puckett, A. Srinivasan, R. W. Keane, J. Bethea, and A. D. Levi. Apoptosis after traumatic human spinal cord injury. J. Neurosurg. 89:911–920 (1998).

    PubMed  CAS  Google Scholar 

  2. M. J. Crowe, J. C. Bresnahan, S. L. Shuman, J. N. Masters, and M. S. Beattie. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 3:73–76 (1997).

    Article  PubMed  CAS  Google Scholar 

  3. S. Casha, W. R. Yu, and M. G. Fehlings. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 103:203–218 (2001).

    Article  PubMed  CAS  Google Scholar 

  4. S. Ramon y Cajal. Degeneration and regeneration of the nervous system. Oxford University Press, London, 1928.

    Google Scholar 

  5. M. Berry. Post-injury myelin-breakdown products inhibit axonal growth: a hypothesis to explain the failure of axonal regeneration in the mammalian central nervous system. Bibl. Anat. 23:1–11 (1982).

    PubMed  Google Scholar 

  6. P. Caroni and M. E. Schwab. Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J. Cell Biol. 106:1281–1288 (1988).

    Article  PubMed  CAS  Google Scholar 

  7. M. Domeniconi and M. T. Filbin. Overcoming inhibitors in myelin to promote axonal regeneration. J. Neurol. Sci. 233:43–47 (2005).

    Article  PubMed  CAS  Google Scholar 

  8. K. C. Wang, J. A. Kim, R. Sivasankaran, R. Segal, and Z. He. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420:74–78 (2002).

    Article  PubMed  CAS  Google Scholar 

  9. F. J. Liuzzi and R. J. Lasek. Astrocytes block axonal regeneration in mammals by activating the physiological stop pathway. Science 237:642–645 (1987).

    Article  PubMed  CAS  Google Scholar 

  10. P. J. Reier, L. J. Stensaas, and L. Guth. The astrocytic scar as an impediment to regeneration in the central nervous system. In C. C. Kao, R. P. Bunge, and P. J. Reier (eds.), Spinal cord reconstruction, Raven, New York, 1983, pp. 163–195.

    Google Scholar 

  11. R. A. Asher, D. A. Morgenstern, P. S. Fidler, K. H. Adcock, A. Oohira, J. E. Braistead, J. M. Levine, R. U. Margolis, J. H. Rogers, and J. W. Fawcett. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J. Neurosci. 20:2427–2438 (2000).

    PubMed  CAS  Google Scholar 

  12. R. A. Asher, D. A. Morgenstern, M. C. Shearer, K. H. Adcock, P. Pesheva, and J. W. Fawcett. Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells. J. Neurosci. 22:2225–2236 (2002).

    PubMed  CAS  Google Scholar 

  13. M. T. Fitch and J. Silver. Activated macrophages and the blood–brain barrier: inflammation after CNS injury leads to increases in putative inhibitory molecules. Exp. Neurol. 148:587–603 (1997).

    Article  PubMed  CAS  Google Scholar 

  14. R. A. Asher, D. A. Morgenstern, L. D. Moon, and J. W. Fawcett. Chondroitin sulphate proteoglycans: inhibitory components of the glial scar. Prog. Brain Res. 132:611–619 (2001).

    PubMed  CAS  Google Scholar 

  15. D. A. Morgenstern, R. A. Asher, and J. W. Fawcett. Chondroitin sulphate proteoglycans in the CNS injury response. Prog. Brain Res. 137:313–332 (2002).

    PubMed  CAS  Google Scholar 

  16. Y. Zhang, J. K. Winterbottom, M. Schachner, A. R. Lieberman, and P. N. Anderson. Tenascin-C expression and axonal sprouting following injury to the spinal dorsal columns in the adult rat. J. Neurosci. Res. 49:433–450 (1997).

    Article  PubMed  CAS  Google Scholar 

  17. F. De Winter, M. Oudega, A. J. Lankhorst, F. P. Hamers, B. Blits, M. J. Ruitenberg, R. J. Pasterkamp, W. H. Gispen, and J. Verhaagen. Injury-induced class 3 semaphorin expression in the rat spinal cord. Exp. Neurol. 175:61–75 (2002).

    Article  PubMed  CAS  Google Scholar 

  18. R. J. Pasterkamp, P. N. Anderson, and J. Verhaagen. Peripheral nerve injury fails to induce growth of lesioned ascending dorsal column axons into spinal cord scar tissue expressing the axon repellent Semaphorin3A. Eur. J. Neurosci. 13:457–471 (2001).

    Article  PubMed  CAS  Google Scholar 

  19. C. Moreau-Fauvarque, A. Kumanogoh, E. Camand, C. Jaillard, G. Barbin, I. Boquet, C. Love, E. Y. Jones, H. Kikutani, C. Lubetzki, I. Dusart, and A. Chedotal. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J. Neurosci. 23:9229–9239 (2003).

    PubMed  CAS  Google Scholar 

  20. P. P. Monnier, A. Sierra, J. M. Schwab, S. Henke-Fahle, and B. K. Mueller. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 22:319–330 (2003).

    Article  PubMed  CAS  Google Scholar 

  21. V. Perrot, J. Vazquez-Prado, and J. S. Gutkind. Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J. Biol. Chem. 277:43115–43120 (2002).

    Article  PubMed  CAS  Google Scholar 

  22. J. M. Swiercz, R. Kuner, J. Behrens, and S. Offermanns. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35:51–63 (2002).

    Article  PubMed  CAS  Google Scholar 

  23. E. J. Rubin, D. M. Gill, P. Boquet, and M. R. Popoff. Functional modification of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of Clostridium botulinum. Mol. Cell Biol. 8:418–426 (1988).

    PubMed  CAS  Google Scholar 

  24. P. Dergham, B. Ellezam, C. Essagian, H. Avedissian, W. D. Lubell, and L. McKerracher. Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22:6570–6577 (2002).

    PubMed  CAS  Google Scholar 

  25. A. E. Fournier, B. T. Takizawa, and S. M. Strittmatter. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 23:1416–1423 (2003).

    PubMed  CAS  Google Scholar 

  26. Z. Jin and S. M. Strittmatter. Rac1 mediates collapsin-1-induced growth cone collapse. J. Neurosci. 17:6256–6263 (1997).

    PubMed  CAS  Google Scholar 

  27. M. Lehmann, A. Fournier, I. Selles-Navarro, P. Dergham, A. Sebok, N. Leclerc, G. Tigyi, and L. McKerracher. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J. Neurosci. 19:7537–7547 (1999).

    PubMed  CAS  Google Scholar 

  28. B. Niederost, T. Oertle, J. Fritsche, R. A. McKinney, and C. E. Bandtlow. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J. Neurosci. 22:10368–10376 (2002).

    PubMed  CAS  Google Scholar 

  29. A. D. Frankel and C. O. Pabo. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189–1193 (1988).

    Article  PubMed  CAS  Google Scholar 

  30. M. Green and P. M. Loewenstein. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179–1188 (1988).

    Article  PubMed  CAS  Google Scholar 

  31. S. Fawell, J. Seery, Y. Daikh, C. Moore, L. L. Chen, B. Pepinsky, and J. Barsoum. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U. S. A 91:664–668 (1994).

    Article  PubMed  CAS  Google Scholar 

  32. S. Conrad, H. J. Schluesener, K. Trautmann, N. Joannin, R. Meyermann, and J. M. Schwab. Prolonged lesional expression of RhoA and RhoB following spinal cord injury. J. Comp. Neurol. 487:166–175 (2005).

    Article  PubMed  CAS  Google Scholar 

  33. C. Brabeck, M. Mittelbronn, K. Bekure, R. Meyermann, H. J. Schluesener, and J. M. Schwab. Effect of focal cerebral infarctions on lesional RhoA and RhoB expression. Arch. Neurol. 60:1245–1249 (2003).

    Article  PubMed  Google Scholar 

  34. J. P. Benoit, N. Faisant, M. C. Venier-Julienne, and P. Menei. Development of microspheres for neurological disorders: from basics to clinical applications. J. Control. Release 65:285–296 (2000).

    Article  PubMed  CAS  Google Scholar 

  35. D. F. Emerich, M. A. Tracy, K. L. Ward, M. Figueiredo, R. Qian, C. Henschel, and R. T. Bartus. Biocompatibility of poly (DL-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant. 8:47–58 (1999).

    PubMed  CAS  Google Scholar 

  36. P. Menei, V. Daniel, C. Montero-Menei, M. Brouillard, A. Pouplard-Barthelaix, and J. P. Benoit. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. Biomaterials 14:470–478 (1993).

    Article  PubMed  CAS  Google Scholar 

  37. K. L. Guan and J. E. Dixon. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192:262–267 (1991).

    Article  PubMed  CAS  Google Scholar 

  38. J. M. Pean, F. Boury, M. C. Venier-Julienne, P. Menei, J. E. Proust, and J. P. Benoit. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res. 16:1294–1299 (1999).

    Article  PubMed  CAS  Google Scholar 

  39. C. Yan, J. H. Resau, M. West, W. L. Rill, and M. Kende. Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by water-in-oil-in-water emulsion technique. J. Control. Release 32:231–241 (1994).

    Article  CAS  Google Scholar 

  40. E. P. Magre and A. P. Sam. Hydrolytic degradation of PLAGA, calculation of rate constants from various types of in-vitro degradation curves. J. Control. Release 48:318–320 (1997).

    Google Scholar 

  41. S. T. Dillon and L. A. Feig. Purification and assay of recombinant C3 transferase. Methods Enzymol. 256:174–184 (1995).

    Article  PubMed  CAS  Google Scholar 

  42. R. Kozma, S. Sarner, S. Ahmed, and L. Lim. Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. Mol. Cell Biol. 17:1201–1211 (1997).

    PubMed  CAS  Google Scholar 

  43. Y. Kloog, J. Axelrod, and I. Spector. Protein carboxyl methylation increases in parallel with differentiation of neuroblastoma cells. J. Neurochem. 40:522–529 (1983).

    Article  PubMed  CAS  Google Scholar 

  44. H. Li, H. C. Chen, and F. L. Huang. Identification of a rapidly dephosphorylating 95-kDa protein as elongation factor 2 during 8-Br-cAMP treatment of N1E115 neuroblastoma cells. Biochem. Biophys. Res. Commun. 217:131–137 (1995).

    Article  PubMed  CAS  Google Scholar 

  45. T. Ishii, E. Satoh, and M. Nishimura. Integrin-linked kinase controls neurite outgrowth in N1E-115 neuroblastoma cells. J. Biol. Chem. 276:42994–43003 (2001).

    Article  PubMed  CAS  Google Scholar 

  46. J. Yamauchi, Y. Miyamoto, A. Sanbe, and A. Tanoue. JNK phosphorylation of paxillin, acting through the Rac1 and Cdc42 signaling cascade, mediates neurite extension in N1E-115 cells. Exp. Cell Res. 312:2954–2961 (2006).

    Article  PubMed  CAS  Google Scholar 

  47. C. G. Pitt, M. M. Gratzl, G. L. Kimmel, J. Surles, and A. Schindler. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. Biomaterials 2:215–220 (1981).

    Article  PubMed  CAS  Google Scholar 

  48. N. Faisant, J. Siepmann, and J. P. Benoit. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 15:355–366 (2002).

    Article  PubMed  CAS  Google Scholar 

  49. J. Wang, B. M. Wang, and S. P. Schwendeman. Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. J. Control. Release 82:289–307 (2002).

    Article  PubMed  CAS  Google Scholar 

  50. J. M. Pean, M. C. Venier-Julienne, F. Boury, P. Menei, B. Denizot, and J. P. Benoit. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release 56:175–187 (1998).

    Article  PubMed  CAS  Google Scholar 

  51. C. Sturesson and J. Carlfors. Incorporation of protein in PLG-microspheres with retention of bioactivity. J. Control. Release 67:171–178 (2000).

    Article  PubMed  CAS  Google Scholar 

  52. W. Friess and M. Schlapp. Modifying the release of gentamicin from microparticles using a PLGA blend. Pharm. Dev. Technol. 7:235–248 (2002).

    Article  PubMed  CAS  Google Scholar 

  53. M. A. Tracy, K. L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, and Y. Zhang. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20:1057–1062 (1999).

    Article  PubMed  CAS  Google Scholar 

  54. W. I. Li, K. W. Anderson, R. C. Mehta, and P. P. Deluca. Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/ evaporation method. J. Control. Release 37:199–214 (1995).

    Article  CAS  Google Scholar 

  55. J. L. Cleland and A. J. Jones. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 13:1464–1475 (1996).

    Article  PubMed  CAS  Google Scholar 

  56. M. Wolf, M. Wirth, F. Pittner, and F. Gabor. Stabilisation and determination of the biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) nanospheres. Int. J. Pharm. 256:141–152 (2003).

    Article  PubMed  CAS  Google Scholar 

  57. M. Morlock, H. Koll, G. Winter, and T. Kissel. Microencapsulation of rh-erythropoietin, using biodegradable poly(,-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm. 43:29–36 (1997).

    Article  CAS  Google Scholar 

  58. H. Sah. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 58:143–151 (1999).

    Article  PubMed  CAS  Google Scholar 

  59. C. Perez-Rodriguez, N. Montano, K. Gonzalez, and K. Griebenow. Stabilization of alpha-chymotrypsin at the CH2Cl2/water interface and upon water-in-oil-in-water encapsulation in PLGA microspheres. J. Control. Release. 89:71–85 (2003).

    Article  PubMed  CAS  Google Scholar 

  60. E. Sahai and M. F. Olson. Purification of TAT-C3 Exoenzyme. In W. E. Balch, C. J. Der, and A. Hall (eds.), Methods in Enzymology—Regulators and Effectors of Small GTPases: Rho Family, Academic Press, 2006, pp. 128–140.

  61. J. Park, J. S. Kim, K. C. Jung, H. J. Lee, J. I. Kim, J. Kim, J. Y. Lee, J. B. Park, and S. Y. Choi. Exoenzyme Tat-C3 inhibits association of zymosan particles, phagocytosis, adhesion, and complement binding in macrophage cells. Mol. Cells 16:216–223 (2003).

    PubMed  CAS  Google Scholar 

  62. V. Sauzeau, E. Le Mellionnec, J. Bertoglio, E. Scalbert, P. Pacaud, and G. Loirand. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ. Res. 88:1102–1104 (2001).

    Article  PubMed  CAS  Google Scholar 

  63. G. Gadea, Y. Boublik, S. Delga, and P. Roux. Efficient production of Clostridium botulinum exotoxin C3 in bacteria: a screening method to optimize production yields. Protein Expr. Purif. 40:164–168 (2005).

    Article  PubMed  CAS  Google Scholar 

  64. X. Z. Liu, X. M. Xu, R. Hu, C. Du, S. X. Zhang, J. W. McDonald, H. X. Dong, Y. J. Wu, G. S. Fan, M. F. Jacquin, C. Y. Hsu, and D. W. Choi. Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. 17:5395–5406 (1997).

    PubMed  CAS  Google Scholar 

  65. S. L. Shuman, J. C. Bresnahan, and M. S. Beattie. Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J. Neurosci. Res. 50:798–808 (1997).

    Article  PubMed  CAS  Google Scholar 

  66. S. D. Grossman, L. J. Rosenberg, and J. R. Wrathall. Temporal–spatial pattern of acute neuronal and glial loss after spinal cord contusion. Exp. Neurol. 168:273–282 (2001).

    Article  PubMed  CAS  Google Scholar 

  67. C. I. Dubreuil, M. J. Winton, and L. McKerracher. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162:233–243 (2003).

    Article  PubMed  CAS  Google Scholar 

  68. I. J. Castellanos, R. Crespo, and K. Griebenow. Poly(ethylene glycol) as stabilizer and emulsifying agent: a novel stabilization approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. J. Control. Release 88:135–145 (2003).

    Article  PubMed  CAS  Google Scholar 

  69. A. Aubert-Pouessel, M. C. Venier-Julienne, A. Clavreul, M. Sergent, C. Jollivet, C. N. Montero-Menei, E. Garcion, D. C. Bibby, P. Menei, and J. P. Benoit. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release 95:463–475 (2004).

    Article  PubMed  CAS  Google Scholar 

  70. S. P. Schwendeman, M. Cardamone, M. R. Brandon, A. Kilbanov, and R. Langer. Stability of proteins and their delivery from biodegradable polymer microspheres. In Microparticulate systems for the delivery of proteins and vaccines, Marcel Dekker, New York, 1996.

  71. J. Yang and J. L. Cleland. Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres. J. Pharm. Sci. 86:908–914 (1997).

    Article  PubMed  CAS  Google Scholar 

  72. A. P. Nicholas, C. McInnis, K. B. Gupta, W. W. Snow, D. F. Love, D. W. Mason, T. M. Ferrell, J. K. Staas, and T. R. Tice. The fate of biodegradable microspheres injected into rat brain. Neurosci. Lett. 323:85–88 (2002).

    PubMed  CAS  Google Scholar 

  73. T. G. Park, W. Lu, and G. Crotts. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (-lactic acid-co-glycolic acid) microspheres. J. Control. Release 33:211–222 (1995).

    Article  CAS  Google Scholar 

  74. S. C. Piscitelli, W. G. Reiss, W. D. Figg, and W. P. Petros. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin. Pharmacokinet. 32:368–381 (1997).

    Article  PubMed  CAS  Google Scholar 

  75. A. Sanchez, M. Tobio, L. Gonzalez, A. Fabra, and M. J. Alonso. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 18:221–229 (2003).

    Article  PubMed  CAS  Google Scholar 

  76. L. Chen, R. N. Apte, and S. Cohen. Characterization of PLGA microspheres for the controlled delivery of IL-1[alpha] for tumor immunotherapy. J. Control. Release 43:261–272 (1997).

    Article  Google Scholar 

  77. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer. Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603 (1994).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Block MD9, 2 Medical Drive, Singapore, 117597, Singapore

    Elaine Y. M. Tan, Janice W. S. Law & Alan Y. W. Lee

  2. Neurobiology Program, Centre for Life Sciences, National University of Singapore, 28 Medical Drive, Singapore, 117456, Singapore

    Janice W. S. Law & Alan Y. W. Lee

  3. Department of Chemical and Biomolecular Engineering, Faculty of Engineering, National University of Singapore, 4 Engineering Drive, Singapore, 117576, Singapore

    Chi-Hwa Wang

Authors
  1. Elaine Y. M. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janice W. S. Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chi-Hwa Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan Y. W. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Y. W. Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, E.Y.M., Law, J.W.S., Wang, CH. et al. Development of a Cell Transducible RhoA Inhibitor TAT-C3 Transferase and its Encapsulation in Biocompatible Microspheres to Promote Survival and Enhance Regeneration of Severed Neurons. Pharm Res 24, 2297–2308 (2007). https://doi.org/10.1007/s11095-007-9454-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-007-9454-6

Key words

Search

Navigation